Table 1. Age and breast cancer biological characteristics at diagnosis compared between NZ European and Māori women.
| Characteristic | NZ European (N = 2304) | Māori (N = 429) | p | ||
|---|---|---|---|---|---|
| n (crude %) | Age adjusted % | n (crude %) | Age adjusted % | ||
| Age | |||||
| Mean ± SD | 61.5 ± 13.9 | 55.6 ± 12.2 | <0.001 | ||
| Median | |||||
| T Stage | |||||
| 1 | 1249 (54.4) | 53.2 | 178 (41.7) | 42.5 | <0.001 |
| 2 | 821 (35.8) | 36.6 | 172 (40.4) | 40.8 | |
| 3 | 100 (4.4) | 4.5 | 27 (6.3) | 5.8 | |
| 4 | 121 (5.3) | 5.8 | 49 (11.5) | 11.0 | |
| Unknown | 13 | 3 | |||
| N stage | |||||
| 0 | 1404 (61.4) | 62.9 | 220 (51.9) | 53.3 | <0.001 |
| 1 | 582 (25.5) | 24.7 | 130 (30.7) | 29.7 | |
| 2 | 188 (8.2) | 7.8 | 40 (9.4) | 9.3 | |
| 3 | 112 (4.9) | 4.6 | 34 (8.0) | 7.7 | |
| Unknown | 18 | 5 | |||
| M Stage | |||||
| 0 | 2197 (95.4) | 94.9 | 379 (88.3) | 88.6 | <0.001 |
| 1 | 107 (4.6) | 5.1 | 50 (11.7) | 11.4 | |
| Stage category | |||||
| I | 972 (42.2) | 41.6 | 142 (33.1) | 34.2 | <0.001 |
| II | 887 (38.5) | 39.1 | 163 (38.0) | 37.5 | |
| III | 338 (14.7) | 14.2 | 74 (17.2) | 16.9 | |
| IV | 107 (4.6) | 5.1 | 50 (11.7) | 11.4 | |
| Histology | |||||
| Ductal | 1831 (81.2) | 80.5 | 352 (85.2) | 85.0 | 0.032 a |
| Lobular | 258 (11.4) | 11.7 | 35 (8.5) | 8.7 | 0.072 b |
| Mixed | 42 (1.9) | 1.8 | 9 (2.2) | 2.3 | |
| Other | 125 (5.5) | 5.9 | 17 (4.1) | 4.0 | |
| Unknown | 48 | 16 | |||
| Grade | |||||
| Grade I | 543 (25.3) | 25.6 | 69 (17.6) | 18.5 | 0.008 |
| Grade II | 1118 (52.1) | 52.7 | 229 (58.4) | 59.7 | |
| Grade III | 485 (22.6) | 21.7 | 93 (23.7) | 21.8 | |
| Unknown | 158 | 38 | |||
| ER/PR | |||||
| ER+/PR+ | 1414 (64.1) | 64.2 | 252 (60.9) | 61.9 | 0.204 |
| ER+/PR- | 430 (19.5) | 20.2 | 75 (18.1) | 18.6 | 0.071 c |
| ER-/PR+ | 28 (1.3) | 1.1 | 8 (1.9) | 1.6 | |
| ER-/PR- | 333 (15.1) | 14.4 | 79 (19.1) | 17.9 | |
| ER or PR Unknown | 99 | 15 | |||
| HER-2 | |||||
| Negative | 1239 (74.8) | 75.2 | 257 (72.4) | 73.8 | 0.091 |
| Equivocal | 135 (8.1) | 8.5 | 21 (5.9) | 6.0 | 0.069 d |
| Positive | 283 (17.1) | 16.3 | 77 (21.7) | 20.2 | |
| Unknown | 647 | 74 | |||
| TNBC e | |||||
| No | 1455 (91.5) | 91.7 | 316 (92.9) | 93.0 | 0.446 |
| Yes | 135 (8.5) | 8.3 | 24 (7.1) | 7.0 | |
| Unknown | 714 | 89 | |||
| Detection method | |||||
| Non-screen | 1443 (62.6) | 64.1 | 300 (69.9) | 68.9 | 0.056 |
| Screen | 861 (37.4) | 35.9 | 129 (30.1) | 31.1 | |
| Comorbidity score | |||||
| 0 | 1903 (82.6) | 79.6 | 304 (70.9) | 67.6 | <0.001 |
| 1–2 | 366 (15.9) | 18.4 | 110 (25.6) | 28.2 | |
| 3+ | 35 (1.5) | 2.0 | 15 (3.5) | 4.1 | |
| Loco-regional therapy | |||||
| BCS with RT | 1082 (41.0) | 40.3 | 153 (27.5) | 27.6 | <0.001 |
| BCS without RT | 196 (14.4) | 13.6 | 30 (15.2) | 14.5 | |
| Mastectomy | 852 (37.0) | 36.8 | 188 (43.8) | 43.3 | |
| No primary surgery | 174 (7.6) | 9.2 | 58 (13.5) | 14.7 | |
| Chemotherapy | |||||
| No | 1580 (68.6) | 73.5 | 270 (62.9) | 67.3 | 0.015 |
| Yes | 724 (31.4) | 26.5 | 159 (37.1) | 32.7 | |
| Endocrine therapy | |||||
| No | 678 (29.4) | 30.3 | 146 (34.0) | 33.8 | 0.041 |
| Yes | 1626 (70.6) | 69.7 | 283 (66.0) | 66.2 | |
| Post 2005 breast cancers | NZ European (N = 1247) | Māori (N = 278) | p | ||
| n (crude %) | Age adjusted % | n (crude %) | Age adjusted % | ||
| HER-2 | |||||
| Negative | 946 (79.5) | 79.9 | 202 (74.8) | 75.9 | 0.072 |
| Equivocal | 65 (5.5) | 5.8 | 11 (4.1) | 4.4 | 0.012 d |
| Positive | 179 (15.0) | 14.3 | 57 (21.1) | 19.7 | |
| Unknown | 57 | 8 | |||
| TNBC e | |||||
| No | 1054 (92.6) | 92.6 | 238 (93.3) | 93.5 | 0.536 |
| Yes | 84 (7.4) | 7.4 | 17 (6.7) | 6.5 | |
| Unknown | 109 | 23 | |||
a ductal vs. other histology types,
b lobular vs. other histology types,
c ER and PR negative vs. other receptor expressions,
d HER-2 positive vs. negative and equivocal,
e triple negative breast cancer